Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
106-120 of 474
ADT Intensification: The Evidence You Can’t Afford to Miss
MinuteCE®ADT Intensification: The Evidence You Can’t Afford to Miss
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Molecular Profiling in mHSPC: Informing Treatment Selection
MinuteCE®Molecular Profiling in mHSPC: Informing Treatment Selection
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Case: Implementing ADT Intensification in mHSPC
MinuteCE®Case: Implementing ADT Intensification in mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
Project Oncology®The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
Nicolas Girard, MD
Louise Lim, MD
Jacob Sands, MD
Stephanie McDonald, MSN, FNP-BC, AOCNP
Addressing Oncology-Related Infertility Through Collaborative Care
Clinician's RoundtableAddressing Oncology-Related Infertility Through Collaborative Care
Irene Su, MD, MSCE
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Project Oncology®6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Steve Jackson, PharmD
Lyudmila A. Bazhenova, MD
- advertisement
Assessing and Interpreting pCR in Perioperative NSCLC
Project Oncology®Assessing and Interpreting pCR in Perioperative NSCLC
Steve Jackson, PharmD
Alexander Spira, MD, PhD, FACP
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
MinuteCE®ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Aditya Bardia, MD, MPH, FASCO
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
- MinuteCE®
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Project Oncology®Navigating Classification of High-Grade Neuroendocrine Neoplasms
Charles Turck, PharmD, BCPS, BCCCP
Rohit Thummalapalli, MD
- advertisement
Key Differences in Pulmonary and Extrapulmonary NEC Management
Project Oncology®Key Differences in Pulmonary and Extrapulmonary NEC Management
Alexandria May, PharmD, BCPS
Lowell B. Anthony, MD, FACP
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Project Oncology®Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Alexandria May, PharmD, BCPS
Chandrikha Chandrasekharan, MBBS
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Oncology and HematologyTROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD